vinflunine,docetaxel,erdafitinib,pembrolizumab
pierre fabre,merck,janssen
['bladder', '#thor']
we have a new + phase 3 #bladdercancer study: #thor presented by with #erdafinitinib (n=136) vs 2l chemo (n=130) which showed an os improvement 12.1 mo vs 7.8 mo hr 0.64 mf/u 15.9mo with os benefit across all subtypes #asco23 
Medical Oncologist, Investigator, Chief, #BladderCancer Section, #GenitourinaryTumors, NCI, NIH #RareTumors #PatientAdvocate, Latina. Views are my own